venBio Global Strategic Fund IV, L.P. bought ATTO
August 6, 2026 · Form 4 insider transaction
venBio Global Strategic Fund IV, L.P. bought 382,352 shares of Attovia Therapeutics, Inc. at $17.00 per share, a transaction worth $6.50M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
382,352
Price
$17.00
Total value
$6.50M
Role10% owner
SecurityCommon Stock
Transaction codeP: Open-market purchase
Transaction dateAugust 6, 2026
Filing dateAugust 10, 2026
Shares owned after4,181,367
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV.